Familial breast cancer: An investigation into the outcome of treatment for early stage disease

被引：45

作者：

Eccles D. ^{[1
]}

Simmonds P. ^{[2
]}

Goddard J. ^{[3
]}

Coultas M. ^{[1
]}

Hodgson S. ^{[4
]}

Lalloo F. ^{[5
]}

Evans G. ^{[5
]}

Haites N. ^{[6
]}

机构：

[1] Department of Human Genetics, Southampton University, Hospitals NHS Trust

[2] CRC Wessex Medical Oncology Unit, Southampton University, Hospitals NHS Trust

[3] Health Care Research Unit, University of Southampton

[4] Guy's Hospital, London

[5] Regional Genetics Service, St Mary's Hospital, Manchester

[6] Medical School, University of Aberdeen, Aberdeen, Forester Hill

来源：

Familial Cancer | 2001年 / 1卷 / 2期

关键词：

BRCA1; Breast cancer; Familial; Recurrence; Survival;

D O I：

10.1023/A:1013867917101

中图分类号：

学科分类号：

摘要：

The purpose of this study was to retrospectively compare the outcomes of treatment in 304 women with familial and sporadic breast cancer to clarify the options for the primary management of familial breast cancer. The majority of women were consecutively ascertained on the basis of either breast cancer diagnosed at age ≤ 40 years or bilateral breast cancer. In addition, known BRCA1 mutation carriers were identified through the genetics services in participating centres. These patients were subdivided into those with a significant family history of breast cancer or known BRCA1 mutation (FH+) and those with no significant family history (FH-). There were no significant differences in age, surgical treatment or adjuvant treatment between the two groups, but there were significantly more women whose nodal status was unknown in the FH+ group. Ipsilateral recurrence occurred in 22.2% of FH+ patients compared with 24.1% of FH- patients (p = 0.774) who underwent breast conserving surgery. There was a striking excess of contralateral breast cancers in the FH+ group (35.9% v 16%, p = 0.0007), with a cumulative risk of contralateral cancer of 36% at 10 years. This was reflected in a non-significant trend toward worse relapse free survival in the FH+ group (p = 0.0563), but no difference was observed in overall survival between the two patient groups (p = 0.142). Similarly, for patients with known BRCA1 mutations, contralateral recurrence occurred more frequently, but other outcomes were not significantly different from the FH- group. Breast conserving treatment is not associated with an increased risk of local recurrence in women with familial breast cancer and the prognosis of these women appears to be similar to that of young women with apparently sporadic breast cancer. However, the risk of contralateral breast cancer is significant in the FH+ group and should be considered in planning primary treatment and follow up.

引用

页码：65 / 72

页数：7

共 43 条

[1]

Ford D., Easton D.F., Bishop D.T., Et al., Risks of cancer in BRCA1-mutation carriers, Lancet, 343, 8899, pp. 692-695, (1994)

[2]

Robson M., Gilewski T., Haas B., Et al., BRCA-associated breast cancer in young women, J Clin Oncol, 16, 5, pp. 1642-1649, (1998)

[3]

Verhoog L.C., Brekelmans C.T., Seynaeve C., Et al., Survival and tumour characteristics of breast-cancer patients with germline mutations of BRCA1, Lancet, 351, pp. 316-321, (1998)

[4]

Pathology of familial breast cancer: Differences between breast cancers in carriers of BRCA1 or BRCA2 mutations and sporadic cases, Lancet, 349, pp. 1505-1510, (1997)

[5]

Marcus J.N., Watson P., Page D.L., Et al., BRCA2 hereditary breast cancer pathophenotype, Breast Cancer Res Treat, 44, 3, pp. 275-277, (1997)

[6]

Lakhani S.R., Jacquemier J., Sloane J.P., Et al., Multifactorial analysis of differences between sporadic breast cancers and cancers involving BRCA1 and BRCA2 mutations [see comments], J Natl Cancer Inst, 90, 15, pp. 1138-1145, (1998)

[7]

Armes J.E., Egan A.J., Southey M.C., Et al., The histologic phenotypes of breast carcinoma occurring before age 40 years in women with and without BRCA1 or BRCA2 germline mutations: A population-based study, Cancer, 83, 11, pp. 2335-2345, (1998)

[8]

Karp S.E., Tonin P.N., Begin L.R., Et al., Influence of BRCA1 mutations on nuclear grade and estrogen receptor status of breast carcinoma in Ashkenazi Jewish women, Cancer, 80, 3, pp. 435-441, (1997)

[9]

Hakansson S., Johannsson O., Johansson U., Et al., Moderate frequency of BRCA1 and BRCA2 germ-line mutations in Scandinavian familial breast cancer, Am J Hum Genet, 60, 5, pp. 1068-1078, (1997)

[10]

Stoppa-Lyonnet D., Ansquer Y., Dreyfus H., Et al., Familial invasive breast cancers: Worse outcome related to BRCA1 mutations, J Clin Oncol, 18, pp. 4053-4059, (2000)

← 1 2 3 4 5 →